GFM
CSTL icon

GF Fund Management’s Castle Biosciences CSTL Stock Holding History

GF Fund Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.9K Buy
648
+75
+13% +$2.46K ﹤0.01% 520
2025
Q4 		$22.3K Sell
573
-51
-8% -$1.64K ﹤0.01% 496
2025
Q3 		$14.2K Sell
624
-92
-13% -$1.87K ﹤0.01% 526
2025
Q2 		$14.6K Hold
716
– – ﹤0.01% 530
2025
Q1 		$14.3K Buy
716
+128
+22% +$3.17K ﹤0.01% 527
2024
Q4 		$15.7K Buy
+588
New +$17.9K ﹤0.01% 492

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GF Fund Management's CSTL Position: Q1 2026 in Review

GF Fund Management increased its Castle Biosciences (CSTL) stake by 13% in Q1 2026, buying an estimated $2.46K and bringing the position to 648 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #520.

GF Fund Management first reported a position in CSTL in Q4 2024 and has held it in 6 quarters since. The position peaked at $22.3K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • GF Fund Management held 648 shares of Castle Biosciences worth $15.9K as of Q1 2026.
  • GF Fund Management bought 75 Castle Biosciences shares in Q1 2026, an estimated $2.46K.
  • Castle Biosciences made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #520 holding.
  • GF Fund Management first reported a position in Castle Biosciences in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Castle Biosciences position peaked at $22.3K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.